Impact Biomedical (IBO) Payables (2022 - 2026)

Impact Biomedical (IBO) has reported Payables for 5 consecutive years, with $467000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 97.96% year-over-year to $467000.0; the trailing twelve-month figure through Jun 2026 stood at $467000.0 (down 97.96% YoY), and the FY2025 full-year result was $347000.0, down 96.38% from the prior year.
• Payables grew to $467000.0 in Q2 2026 per IBO's latest filing, from $374000.0 in the prior quarter.
• Across five years, Payables topped out at $23.5 million in Q3 2025 and bottomed at $347000.0 in Q4 2025.
• Historically, Payables has averaged $10.3 million across 5 years, with a median of $11.3 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Payables surged 2164.19% in 2025, then sank 97.96% in 2026.
• Over 5 years, Payables stood at $10.5 million in 2022, then grew by 22.56% to $12.9 million in 2023, then dropped by 25.69% to $9.6 million in 2024, then tumbled by 96.38% to $347000.0 in 2025, then jumped by 34.58% to $467000.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $467000.0, $374000.0, and $347000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.